Free Trial
NASDAQ:VERV

Verve Therapeutics Q3 2023 Earnings Report

Verve Therapeutics logo
$4.38 -0.79 (-15.21%)
As of 02:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Verve Therapeutics EPS Results

Actual EPS
-$0.72
Consensus EPS
-$0.90
Beat/Miss
Beat by +$0.18
One Year Ago EPS
N/A

Verve Therapeutics Revenue Results

Actual Revenue
$3.10 million
Expected Revenue
$0.96 million
Beat/Miss
Beat by +$2.14 million
YoY Revenue Growth
+244.40%

Verve Therapeutics Announcement Details

Quarter
Q3 2023
Time
Before Market Opens
Conference Call Date
Tuesday, November 7, 2023
Conference Call Time
1:33PM ET

Upcoming Earnings

Verve Therapeutics' Q1 2025 earnings is scheduled for Wednesday, May 14, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Verve Therapeutics Earnings Headlines

Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.
J.P. Morgan Sticks to Their Hold Rating for Verve Therapeutics (VERV)
See More Verve Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Verve Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verve Therapeutics and other key companies, straight to your email.

About Verve Therapeutics

Verve Therapeutics (NASDAQ:VERV), a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

View Verve Therapeutics Profile

More Earnings Resources from MarketBeat